{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:14:53Z","timestamp":1783577693099,"version":"3.55.0"},"reference-count":17,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The programmed death-1 (PD-1) receptor plays a major physiological role in the maintenance of immune tolerance and, by interaction with its ligands (PD-L1 and PD-L2), prevents the development of multiple immune-mediated diseases. There is growing evidence of the PD-1\/PD-L1 pathway playing an important role in the pathogenesis of psoriasis. In total, 84 subjects with psoriasis were included in this study, together with 29 healthy subjects as a control group. Twenty-eight of the psoriatic patients were treated with biologic therapy (TNF-alpha, interleukin (IL)-12\/23, or IL-17 inhibitors). The amounts of PD-1- and PD-L1-positive T-cells in peripheral blood were evaluated using flow cytometry. Significantly lower levels of peripheral blood mononuclear cells (PBMCs) with the expression of PD-1 and PD-L1 were found in psoriatic patients compared to healthy individuals, i.e., CD3\/PD-1-, CD3\/PD-L1-, CD4\/PD-1-, CD4\/PD-L1-, CD8\/PD-L1-, CD19\/PD-1-, and CD19\/PD-L1-positive cells. Biologic treatment resulted in the elevation of CD3\/PD-L1- and CD8\/PD-L1- and a decrease in CD8\/PD-1-positive PBMCs. Our results confirm previous observations of the PD-1\/PD-L1 pathway being disrupted in psoriasis, and that these disturbances may play an important role in development of the disease. Biologic drugs may reverse several abnormalities observed within this pathway, which may explain their excellent efficacy in the treatment of psoriasis. Further research should be conducted to fully explain the results obtained.<\/jats:p>","DOI":"10.3390\/jcm12134179","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T02:09:17Z","timestamp":1687399757000},"page":"4179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Impact of Biologic Treatment on PD-1\/PD-L1 Pathway Disturbances in Psoriasis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-7840","authenticated-orcid":false,"given":"Micha\u0142","family":"Adamczyk","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4106-3051","authenticated-orcid":false,"given":"Joanna","family":"Bartosi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland"},{"name":"Department of Cosmetology and Aesthetic Dermatology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3517-6711","authenticated-orcid":false,"given":"Dorota","family":"Raczkiewicz","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, School of Public Health, Center of Postgraduate Medical Education, 01-826 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4599-6249","authenticated-orcid":false,"given":"Anna","family":"Michalak-Stoma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-9870","authenticated-orcid":false,"given":"Dorota","family":"Krasowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.5114\/ada.2021.112274","article-title":"PD1\/PD-L1 pathway in psoriasis and psoriatic arthritis: A review","volume":"38","author":"Adamczyk","year":"2021","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","article-title":"The inflammatory response in psoriasis: A comprehensive review","volume":"50","author":"Deng","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","first-page":"815","article-title":"Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis","volume":"127","author":"Zakrzewska","year":"2017","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.17219\/acem\/78020","article-title":"The expression of selected molecular markers of immune tolerance in psoriatic patients","volume":"27","author":"Purkot","year":"2018","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.jid.2022.06.006","article-title":"The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis","volume":"142","author":"Tanaka","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: An updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/08916930500124072","article-title":"PD-1\/PD-L pathway and autoimmunity","volume":"38","author":"Okazaki","year":"2005","journal-title":"Autoimmunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10753-015-0132-2","article-title":"Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis","volume":"38","author":"Peled","year":"2015","journal-title":"Inflammation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","article-title":"The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis","volume":"62","author":"Raptopoulou","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4049\/jimmunol.1500448","article-title":"Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate \u03b3\u03b4-Low T Cells","volume":"195","author":"Imai","year":"2015","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cei.12949","article-title":"Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1","volume":"188","author":"Bommarito","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_16","first-page":"5385102","article-title":"Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients","volume":"2017","author":"Zakrzewska","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5114\/ada.2018.75609","article-title":"Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis","volume":"35","author":"Zakrzewska","year":"2018","journal-title":"Postep. Dermatol. Alergol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:57:48Z","timestamp":1760126268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":17,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12134179"],"URL":"https:\/\/doi.org\/10.3390\/jcm12134179","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}